CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sing, G. K.
Right arrow Articles by Longo, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sing, G. K.
Right arrow Articles by Longo, D. L.

Cell Growth & Differentiation, Vol 1, Issue 11 549-557, Copyright © 1990 by American Association of Cancer Research


ARTICLES

Growth inhibition of a human lymphoma cell line: induction of a transforming growth factor-beta-mediated autocrine negative loop by phorbol myristate acetate

GK Sing, FW Ruscetti, M Beckwith, JR Keller, L Ellingsworth, WJ Urba and DL Longo
Division of Cancer Treatment National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.

Transforming growth factor-beta (TGF-beta) exerts profound inhibitory effects on a number of cell types, including normal B- and T-lymphocytes. In contrast, we have found a number of lymphoid tumor cell lines to be insensitive to the antiproliferative effects of TGF-beta 1 or TGF-beta 2. Binding and cross-linking with radioiodinated TGF-beta 1 demonstrated either low or absent expression of all three TGF-beta receptor species on three B-cell tumor lines, but T-cell and non-T, non-B tumors expressed large numbers of receptors. Treatment of the B-cell lines with phorbol 12-myristate 13-acetate (PMA) induced the expression of TGF-beta receptors and inhibited proliferation in all three lines in a dose- and time-dependent manner. The cell lines constitutively produced TGF-beta mRNA and released small amounts of latent TGF-beta; however, PMA induced the release of active TGF-beta. A neutralizing antibody to TGF-beta was able to reverse the PMA-induced growth inhibition of the malignant lymphoma cell line, RL, and addition of exogenous TGF-beta reversed the effect of the neutralizing antibody. Thus, TGF-beta can inhibit human lymphoma cell growth in vitro through an autocrine mechanism. Some lymphoma cells appear to have escaped from TGF-beta negative regulation by failing to express functional TGF-beta receptors and/or by failing to secrete active TGF-beta receptors and/or by failing to acts to inhibit lymphoma cell growth is by inducing the expression of TGF-beta receptors and the secretion of active TGF-beta, thereby reestablishing an autocrine growth-inhibitory loop.


This article has been cited by other articles:


Home page
Mol Cancer ResHome page
G. Chen, P. Ghosh, and D. L. Longo
Distinctive Mechanism for Sustained TGF-{beta} Signaling and Growth Inhibition: MEK1 Activation-Dependent Stabilization of Type II TGF-{beta} Receptors
Mol. Cancer Res., January 1, 2011; 9(1): 78 - 89.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Chen, P. Ghosh, H. Osawa, C. Y. Sasaki, L. Rezanka, J. Yang, T. J. O'Farrell, and D. L. Longo
Resistance to TGF-{beta}1 correlates with aberrant expression of TGF-{beta} receptor II in human B-cell lymphoma cell lines
Blood, June 15, 2007; 109(12): 5301 - 5307.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. B. Brunschwig, K. Wilson, D. Mack, D. Dawson, E. Lawrence, J. K.V. Willson, S. Lu, A. Nosrati, R. M. Rerko, S. Swinler, et al.
PMEPA1, a Transforming Growth Factor-{beta}-induced Marker of Terminal Colonocyte Differentiation Whose Expression Is Maintained in Primary and Metastatic Colon Cancer
Cancer Res., April 1, 2003; 63(7): 1568 - 1575.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. R. Amoroso, N. Huang, A. B. Roberts, M. Potter, and J. J. Letterio
Consistent loss of functional transforming growth factor {beta} receptor expression in murine plasmacytomas
PNAS, January 6, 1998; 95(1): 189 - 194.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
T. Sasaguri, A. Ishida, C. Kosaka, H. Nojima, and J. Ogata
Phorbol Ester Inhibits the Phosphorylation of the Retinoblastoma Protein without Suppressing Cyclin D-associated Kinase in Vascular Smooth Muscle Cells
J. Biol. Chem., April 5, 1996; 271(14): 8345 - 8351.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
V. Buchman, M Sporn, and A. Davies
Role of transforming growth factor-beta isoforms in regulating the expression of nerve growth factor and neurotrophin-3 mRNA levels in embryonic cutaneous cells at different stages of development
Development, January 6, 1994; 120(6): 1621 - 1629.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1990 by the American Association of Cancer Research.